MadridTeacher.com

Bristol-Myers Squibb - Cloze

Thomas Fieselmann
Activity by Thomas Fieselmann
Modified extracts from Wikipedia.

Fill in all the gaps with the missing words, then press "Check" to check your answers. Use the "Hint" button to get a free letter if an answer is giving you trouble. You can also click on the "[?]" button to get a clue. Click the this button again for another letter. You can also click on "[?]" for a different hint. Note that you will lose points if you ask for hints or clues!

Rellena los espacios en blanco con las palabras que faltan. Haz click en "Check" para comprobar tus aciertos. Si te resulta difícil la respuesta utiliza el botón "Hint" y te revelará una letra de la casilla en la que te encuentres, puedes clickear varias veces en "Hint" y te dará cada vez una letra más de la palabra. Para obtener ayuda también puedes clickear en el botón "[?]" y te dará una pista. Perderás puntos con las pistas.


Listen:
Slow:    Normal:
                       
   acquisitions      awarded      board      CEO      driven      enhancing      founded      groundbreaking      headquartered      manufactures      measure      merger      pension      premium      prevail      R&D      restructuring      shareholders      sharpen      sites      splitting      stock      streamlining      treatments   
Bristol-Myers Squibb
Type Public
Traded as NYSE: BMY
Industry Pharmaceuticals
Founded 1887
Headquarters New York City, United States
Revenue US$18.8 Billion (FY 2009)
Employees 28,000 (2010)

Bristol-Myers Squibb (NYSE: BMY), often referred to as BMS, is a pharmaceutical company, in New York City. The company was formed in 1989, following the of its predecessors Bristol-Myers and the Squibb Corporation. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers was in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York.
Lamberto Andreotti became the company's on May 4, 2010. Former CEO James M. Cornelius remains Chairman of the of Directors.
Bristol-Myers Squibb prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients over serious diseases."
BMS' primary sites are located in Princeton, New Jersey (formerly Squibb) and Wallingford, Connecticut (formerly Bristol-Myers), with other in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, Tokyo, Japan and Bangalore, India.
A major involves focusing on the pharmaceutical business and biologic products along with productivity initiatives and cost-cutting and business operations through a multi-year program of on-going layoffs. As another cost-cutting , Bristol-Myers also reduced subsidies for health-care to retirees and plans to freeze their plan at the end of 2009.
In November 2009, Bristol-Myers Squibb announced that it was " off" Mead Johnson Nutrition by offering BMS shareholders the opportunity to exchange their for shares in Mead Johnson. According to Bristol-Myers Squibb, this move was expected to further the company's focus on biopharmaceuticals.
In 1999, President Clinton Bristol-Myers Squibb the National Medal of Technology, the nation's highest recognition for technological achievement, "for extending and human life through innovative pharmaceutical research and development and for redefining the science of clinical study through and hugely complex clinical trials that are recognized models in the industry."
BMS is a Fortune 500 Company (#114 in the 2010 list). Newsweek's 2009 Green Ranking recognized Bristol-Myers Squibb as 8th among 500 of the largest U.S. corporations. Also, BMS was included in the 2009 Dow Jones Sustainability North America Index of leading sustainability- companies.
In August 2009, BMS acquired the biotechnology firm Medarex as part of the company's "String of Pearls" strategy of alliances, partnerships, and . In October 2010, the company acquired ZymoGenetics, securing an existing product as well as pipeline assets in hepatitis C, cancer, and other therapeutic areas.
Bristol-Myers Squibb Corp. agreed to pay around $2.5 billion in cash to buy Inhibitex, Inc. in concern to compete with Gilead/Pharmasset to produce Hepatitis C drugs. The settlement will be finished in 2 months with Inhibitex's ’ acceptance of 126 percent price over the average previous 20 trading days ended on January 6, 2012.
In 2012, the company donated $6.9 million to the HealthWell Foundation, which provides financial assistance to eligible people for covering co-insurance, co-payments, healthcare premiums, and deductibles for certain .